

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form DEFA14A  
April 25, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**SCHEDULE 14A**  
**Proxy Statement Pursuant to Section 14(a) of**  
**the Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement  
Definitive Proxy Statement  
Definitive Additional Materials  
Soliciting Material under §240.14a-12

**Confidential, For Use of the Commission Only (as  
permitted by Rule 14a-6(e)(2))**

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

**(Name of Registrant as Specified In Its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.

(1) Title of each class of securities to which transaction applies:

- (2) Aggregate number of securities to which transaction applies:
  
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  
- (4) Proposed maximum aggregate value of transaction:
  
- (5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:
  
- (2) Form, Schedule or Registration Statement No.:
  
- (3) Filing Party:
  
- (4) Date Filed:

*The following communication was sent to certain beneficial holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:*







*The following communication was sent to certain registered holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:*

Shareholder Services  
P.O. Box 64507

St. Paul, MN 55164-0507

**Teva Pharmaceutical Industries Limited**  
**2018 ANNUAL MEETING OF SHAREHOLDERS**  
**June 5, 2018**  
**4:30 p.m. (Israel Time)**  
**Teva's executive offices**  
**5 Basel Street**  
**Petach Tikva, 4951033 Israel**

Directions to the Teva Pharmaceutical Industries Limited 2018 Annual Meeting of Shareholders are available in the proxy statement which can be viewed at [proxydocs.com/teva](http://proxydocs.com/teva).

**Important Notice Regarding the Availability of Proxy Materials for the**  
**Shareholder Meeting to be Held on June 5, 2018.**

Notice is hereby given that the 2018 Annual Meeting of Shareholders (the **meeting**) of Teva Pharmaceutical Industries Limited will be held at Teva's executive offices at 5 Basel Street, Petach Tikva, 4951033 Israel on **June 5, 2018 at 4:30 p.m. (Israel Time)**.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

The proxy statement and Annual Report are available at [www.proxydocs.com/teva](http://www.proxydocs.com/teva).

If you want to receive a paper copy or an email with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side of this Notice on or before **May 22, 2018** to facilitate timely delivery.

**Matters intended to be acted upon at the meeting are listed below.**

1. To appoint the following persons to the Board of Directors: Rosemary A. Crane, Gerald M. Lieberman and Professor Ronit Satchi-Fainaro as directors to serve until our 2021 annual meeting of shareholders.

2. To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.
3. To recommend, on a non-binding advisory basis, to hold a non-binding advisory vote to approve the compensation for Teva's named executive officers every one, two or three years.
4. To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2019 annual meeting of shareholders.
5. To approve an amendment and restatement of Teva's 2008 Employee Stock Purchase Plan for U.S. Employees. In addition, shareholders will consider Teva's annual consolidated financial statements for the year ended December 31, 2017.

**The Board of Directors recommends that you vote FOR Proposals 1, 2, 4 and 5.**

**The Board of Directors recommends that you vote ONE YEAR with respect to Proposal 3.**

**THIS IS NOT A FORM FOR VOTING**

**You may immediately vote your proxy on the Internet at:**

**[www.proxypush.com/teva](http://www.proxypush.com/teva)**

Use the Internet to vote your proxy 24 hours a day, 7 days a week, until 11:59 p.m. (Eastern Time) on June 3, 2018.

Please have this Notice and the last four digits of your Social Security Number or Tax Identification Number available. Follow the instructions to vote your proxy.



**To request a paper or email copy of the proxy materials, which include the Voting Instruction Card, proxy statement and Annual Report, please contact us via:**

**Internet/Mobile Device** Access the Internet and go to [www.investorelections.com/teva](http://www.investorelections.com/teva). Follow the instructions to log in and order copies.

**Telephone** Call us free of charge at 1-866-870-3684 in the U.S. or Canada, using a touch-tone phone, and follow the instructions to log in and order copies.

**Email** Send us an email at [paper@investorelections.com](mailto:paper@investorelections.com) with Teva Materials Request in the subject line. The email must include:

The 11-digit control # located in the box in the upper right hand corner on the front of this notice.

Your preference to receive printed materials via mail **-or-** to receive an email with links to the electronic materials.

If you choose email delivery you must include the email address.

If you would like this election to apply to delivery of material for all future meetings, write the word Permanent and include the last 4 digits of your Tax ID number in the email.

In order to ensure timely delivery, you must request the information no later than May 22, 2018.

### **Important Information about the Notice of Proxy Materials**

This Notice Regarding the Online Availability of Proxy Materials (Notice) is provided to shareholders in place of the printed materials for the upcoming meeting.

#### **Information about the Notice:**

In 2007, the Securities and Exchange Commission adopted a voluntary rule permitting Internet-based delivery of proxy materials. Companies can now send notices, rather than printed proxy materials to shareholders. This may help lower mailing, printing and storage costs for the company, while minimizing environmental impact. This Notice contains specific information regarding the meeting, proposals and the Internet site where the proxy materials may be found.

#### **To view the proxy materials online:**

Please refer to the instructions in this Notice on how to access and view the proxy materials online, including the Voting Instruction Card, Annual Report and proxy statement.

#### **To receive paper copies of the proxy materials:**

Please refer to the instructions in this Notice on how to request hard copies of proxy materials via phone, email or Internet.

*The following communication was sent to certain holders of its ordinary shares by Teva Pharmaceutical Industries Limited:*

**TEVA PHARMACEUTICAL INDUSTRIES  
LIMITED**

**2018 ANNUAL MEETING OF SHAREHOLDERS**

**June 5, 2018**

**4:30 p.m. (Israel time)**

**Teva's executive officers**

**5 Basel Street**

**Petach Tikva, 4951033 Israel**

Directions to the Teva Pharmaceutical Industries  
Limited

2018 Annual Meeting of Shareholders are available in  
the

proxy statement which can be viewed at

[www.tevapharm.com/2018proxymaterials](http://www.tevapharm.com/2018proxymaterials).

**Important Notice Regarding the Availability of Proxy Materials for the**

**Shareholder Meeting to be Held on June 5, 2018.**

Notice is hereby given that the 2018 Annual Meeting of Shareholders (the **meeting**) of Teva Pharmaceutical Industries Limited (**Teva**) will be held at 5 Basel Street, Petach Tikva, 4951033 Israel on June 5, 2018 at 4:30 p.m. (Israel time).

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for voting.

The Proxy Statement and Annual Report are available at [www.tevapharm.com/2018proxymaterials](http://www.tevapharm.com/2018proxymaterials).

If you want to receive a paper copy or an e-mail with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 22, 2018 to facilitate timely delivery.

**Matters intended to be acted upon at the meeting are listed below.**

1. To appoint the following persons to the Board of Directors: Rosemary A. Crane, Gerald M. Lieberman and Professor Ronit Satchi-Fainaro as directors to serve until our 2021 annual meeting of shareholders.
2. To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.
3. To recommend, on a non-binding advisory basis, to hold a non-binding advisory vote to approve the compensation for Teva's named executive officers every one, two or three years.
4. To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2019 annual meeting of shareholders.
5. To approve an amendment and restatement of Teva's 2008 Employee Stock Purchase Plan for U.S. Employees. In addition, shareholders will consider Teva's annual consolidated financial statements for the year ended December 31, 2017.

**The Board of Directors recommends that you vote FOR Proposals 1, 2, 4 and 5.**

**The Board of Directors recommends that you vote ONE YEAR with respect to Proposal 3.**

**To request paper copies of the proxy materials, which include the proxy card, proxy statement and annual report, please contact us via:**

**Internet/Mobile** Access the Internet and go to [www.tevapharm.com/InfoRequest](http://www.tevapharm.com/InfoRequest). Follow the instructions to order copies.

**Telephone** Call Investor Relations in the United States at +1 (215) 591-8912 or in Israel at +972 (3) 926-7756.

**Email** Send us an email at [TevaIR@tevapharm.com](mailto:TevaIR@tevapharm.com) with "Teva Materials Request" in the subject line. The email must include:

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form DEFA14A

Your preference to receive printed materials via mail *-or-* to receive an email with links to the electronic materials.

If you choose email delivery you must include the email address.

If you would like this election to apply to delivery of material for all future meetings, write the word  
Permanent .

In order to ensure timely delivery, you must request the information no later than May 22, 2018.